Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- CORT
- Price
- 41.30
- Stock movement up
- +4.99 (13.74%)
- Company name
- Corcept Therapeutics Incorporated
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 4.34B
- Ent value
- 4.41B
- Price/Sales
- 5.86
- Price/Book
- 6.87
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 41.30
- Forward P/E
- 59.68
- PEG
- -
- EPS growth
- 9.89%
- 1 year return (CAGR)
- -32.42%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CORT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 41.30 |
| Price to OCF | 26.68 |
| Price to FCF | 26.72 |
| Price to EBITDA | 59.95 |
| EV to EBITDA | 60.87 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.86 |
| Price to Book | 6.87 |
| EV to Sales | 5.95 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 105.19M |
| EPS (TTM) | 0.88 |
| FCF per share (TTM) | 1.36 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 741.17M |
| Gross profit (TTM) | 727.78M |
| Operating income (TTM) | 65.57M |
| Net income (TTM) | 105.19M |
| EPS (TTM) | 0.88 |
| EPS (1y forward) | 0.69 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 98.19% |
| Operating margin (TTM) | 8.85% |
| Profit margin (TTM) | 14.19% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 125.14M |
| Net receivables | 73.53M |
| Total current assets | 541.13M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 6.87M |
| Total assets | 823.61M |
| Accounts payable | 34.45M |
| Short/Current long term debt | 6.36M |
| Total current liabilities | 172.26M |
| Total liabilities | 191.71M |
| Shareholder's equity | 631.90M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 162.85M |
| Capital expenditures (TTM) | 282.00K |
| Free cash flow (TTM) | 162.57M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 16.65% |
| Return on Assets | 12.77% |
| Return on Invested Capital | 16.62% |
| Cash Return on Invested Capital | 25.68% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 41.51 |
| Daily high | 43.50 |
| Daily low | 40.46 |
| Daily Volume | 5.89M |
| All-time high | 114.22 |
| 1y analyst estimate | 91.00 |
| Beta | 0.20 |
| EPS (TTM) | 0.88 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 18 Feb 2026 |
Downside potential
Loading...
Downside potential data
| CORT | S&P500 | |
| Current price drop from All-time high | -63.84% | -0.89% |
| Highest price drop | -69.59% | -19.00% |
| Date of highest drop | 16 Jan 2026 | 8 Apr 2025 |
| Avg drop from high | -26.91% | -2.49% |
| Avg time to new high | 21 days | 6 days |
| Max time to new high | 205 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
4.34B
Marketcap category
Mid-cap
Description
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Employees
500
Website
Investor relations
-
SEC filings
CEO
Joseph K. Belanoff
Country
USA
City
Menlo Park
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page